You are here: Industry Insights > Weekly Pharma News Review

News List

Weekly Pharma News Review | PharmaSources.com （Feb.6th - 10th, 2023） Caicai
February 13, 2023
A new indication of Pfizer's tofacitinib sustained release tablet was approved in China; Phase III study of obesity indication of Eli Lilly's Tirzepatide succeeded in China.
Weekly Pharma News Review | PharmaSources.com (0130-0203) PharmaSources.com
February 06, 2023
NMPA announced the emergency drug review and approval, and conditionally approved the first-in-class innovative drugs, Simnotrelvir Tablets/Ritonavir Tablets of Hainan Simcere Pharmaceutical and Renmindevir of Shanghai Wangshi Biological Technology.
Weekly Pharma News Review | PharmaSources.com (April 11 to 15) Yefenghong
April 20, 2022
The sharp crushing in the stock prices of Chinese vaccine leader companies Zhifei Biological and Wantai Biological is the most-watched news this week.
Weekly Pharma News Review | PharmaSources.com (March 28 to April 1) PharmaSources.com
April 07, 2022
The failure of Phase III clinical trials targeting the popular target TIGIT monoclonal antibody has once again put tumor immunotherapy on the radar this week. The pharma news review of this week from March 28 to April 1 covers a total of 25 pieces of news
Weekly Pharma News Review | PharmaSources.com (March 21 to 25) PharmaSources/Caicai
March 30, 2022
Henlius PD-1 was launched this week, becoming the 7th China-made PD-1 monoclonal antibody and the 13th PD-1/PD-L1 monoclonal antibody that was marketed in China.
Weekly Pharma News Review | PharmaSources.com (March 14 to 18) PharmaSources/Caicai
March 25, 2022
One of the most exciting news of this week was the marketing approval of duvelisib capsules, a dual PI3K inhibitor introduced by CSPC Pharmaceutical Group Co., Ltd.
Weekly Pharma News Review | PharmaSources.com (March 7 to 12) PharmaSources.com
March 16, 2022
The news review of this week is from March 7 to 12, covering a total of 20 pieces of information in 4 sections, i.e. review, R&D, business, and listing.